Rare diseases. Cancer. Diabetes. Brain Disorders, and much more! We have expertise across 27+ therapeutic areas, and we guarantee to deliver the latest scoop to your inbox—Miss not to subscribe to our Newsletters.
Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or complete cessation of blood flow to a portion of the myocardium. Myocardial infarction may be “silent,” and go undetected, or it could be a catastrophic event leading to hemodynamic deterioration and sudden death. Most myocardial infarctions are due to underlying coronary artery disease, the leading cause of death in the United States. In myocardial infarction, there are 60+ drugs in different phases of de...
Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7,00,000 people each year. Currently, the AIS domain constitutes an immensely robust pipeline with more than 35+ drugs under different phases of development.
Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis. It is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Over the past few years, a dramatic improvement in outcomes of rheumatoid arthritis has been observed due to the direct consequence of paradigm shifts in the treatment. Conventional DMARDs (csDMARDS) and methotrexate (MTX) are part of the first treatment...
Gain rich insights into the pharmaceutical and healthcare market through DelveInsight’s pictorial representations of market insights, epidemiological trends, emerging therapies, and much more about indications.
The pharmaceutical and healthcare market is continuously changing and evolving owing to several facets, including new launches, unexpected failures, and unprecedented situations. Do not lose yourself in the ocean of information, and keep track of essential happenings through DelveInsight’s blogs. Subscribe to us for more information.
29 Sep
Quick Facts about Netherton Syndrome Netherton syndrome, a less common form of ichthyosis, is a monogenic cutaneous condition characterized by congenital scaly erythroderma, evolving into typical erythematous patches with peripheral scaling, hair shaft abnormalities, and atopic manifestation. ...
28 Sep
Orthofix Launched the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures On September 20, 2023, Orthofix Medical Inc., a leading global spine and orthopedics company, launched the Galaxy Fixation Gemini™ system. It is a stable external fixa ...
27 Sep
It is not surprising that the healthcare sector is undergoing a significant transition in an era characterized by technological developments and the digitization of almost every aspect of our lives. The development of smart medical devices is a shining illustration of how technology has advanced in ...
26 Sep
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of pati ...
25 Sep
Orchard Therapeutics’ Biologics License Application for OTL-200, a gene therapy under investigation for metachromatic leukodystrophy treatment, has been accepted by the FDA. This rare disease treatment received approval in Europe back in 2020. Notably, the FDA has granted Orchard’s application Prio ...
22 Sep
On September 15, the FDA authorized GSK’s oral medication momelotinib, now known as Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis is a disorder where normal bone marrow tissue is slowly substituted by fibrous, scar-like material. It is categorized as a form of chr ...
